These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM; Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551 [TBL] [Abstract][Full Text] [Related]
10. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity. Kang HG; Kim TY; Han J; Han SH Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Gunay M; Sukgen EA; Celik G; Kocluk Y Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302 [TBL] [Abstract][Full Text] [Related]
12. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359 [TBL] [Abstract][Full Text] [Related]
13. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor. Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G; Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554 [TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Sukgen EA; Koçluk Y Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M Br J Ophthalmol; 2019 Sep; 103(9):1332-1336. PubMed ID: 30514709 [TBL] [Abstract][Full Text] [Related]
16. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children. Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986 [TBL] [Abstract][Full Text] [Related]
18. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. Stahl A; Krohne TU; Eter N; Oberacher-Velten I; Guthoff R; Meltendorf S; Ehrt O; Aisenbrey S; Roider J; Gerding H; Jandeck C; Smith LEH; Walz JM; JAMA Pediatr; 2018 Mar; 172(3):278-286. PubMed ID: 29309486 [TBL] [Abstract][Full Text] [Related]
19. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964 [TBL] [Abstract][Full Text] [Related]
20. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants. Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]